Elizabeth E. Morgan

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

Scott J. Hecker, K. Raja Reddy, Maxim Totrov et al. · Journal of Medicinal Chemistry · 2015 · 405 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

Keith S. Kaye, Tanaya Bhowmick, Symeon Metallidis et al. · JAMA · 2018 · 306 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

David C. Griffith, Jeffery S. Loutit, Elizabeth E. Morgan et al. · Antimicrobial Agents and Chemotherapy · 2016 · 79 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides

Larry W. Moreland, Elizabeth E. Morgan, T. C. Adamson et al. · Arthritis & Rheumatism · 1998 · 74 citations

Life Sciences, Immunology, Pharmacotherapy +17

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

Patrick A. Flume, Donald R. VanDevanter, Elizabeth E. Morgan et al. · Journal of Cystic Fibrosis · 2016 · 72 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17